Please assess the completion status of the following clinical trial:

Trial Title: A Study to Assess Safety and Efficacy in Participants Age 40 to 55 With Presbyopia (Old Eye) Who Receive AGN-190584 in Both Eyes Twice Daily

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~- Objective and subjective evidence of presbyopia.~Exclusion Criteria:~* Corneal abnormalities (including keratoconus, corneal scar, Fuchs' endothelial dystrophy, guttata, or edema) in either eye that are likely to interfere with visual acuity.~* Narrow iridocorneal angles (Shaffer grade \<=2 or lower on gonioscopy examination), history of angle-closure glaucoma, or previous iridotomy.~* Diagnosis of any type of glaucoma or ocular hypertension.~* History of cataract surgery, phakic intraocular lens surgery, corneal inlay surgery, radial keratotomy, or any intraocular surgery.~* Use of temporary or permanent punctal plugs or history of punctal cautery in one or both eyes.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- Vehicle (Type: PLACEBO_COMPARATOR): Participants received vehicle, one drop bilaterally (in each eye), twice daily (BID), with a gap of 6 hours between both doses, for up to 14 days.
- AGN-190584 (Type: EXPERIMENTAL): AGN-190584 ophthalmic solution, one drop bilaterally (in each eye), BID, with a gap of 6 hours between both doses, for up to 14 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).